Solana Beach, CA, May 01, 2016 --(PR.com
)-- Sentynl Therapeutics, Inc. (“Sentynl”) announced that it acquired the rights to market Abstral® in the U.S. from Galena Biopharma.
Abstral® is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. For complete information regarding Abstral®, please visit Sentynl.com/Abstral
and see below for the boxed warning and Important Safety Information.
About Sentynl Therapeutics.
Sentynl provides healthcare professionals with treatment solutions that enable them to meet the needs of individual patients. Sentynl’s highly experienced and knowledgeable management team has previously built multiple successful pharmaceutical companies. With a focus on commercialization, Sentynl looks to source effective and well differentiated products across a broad spectrum of therapeutic areas.
Sentynl is committed to the highest ethical standards and compliance with all applicable laws, regulations, and industry guidelines. In order to complement its existing product portfolio and further leverage its commercial infrastructure, Sentynl currently seeks product licensing and acquisition opportunities. Target acquisition opportunities include late stage development programs and marketed products in specialty pharmaceuticals. Please visit http://www.sentynl.com/business-development/ for more information or contact us at firstname.lastname@example.org.
[Important Safety Information Follows]
Warning: Risk of Respiratory Depression, Medication Errors, Abuse Potential Respiratory Depression
Fatal respiratory depression has occurred in patients treated with immediate-release transmucosal fentanyl, including following use in opioid non-tolerant patients and improper dosing.
The substitution of Abstral for any other fentanyl product may result in fatal overdose. Due to the risk of respiratory depression, Abstral is contraindicated in the management of acute or postoperative pain including headache/migraine and in opioid non-tolerant patients.
Abstral must be kept out of reach of children.
The concomitant use of Abstral with CYP3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.
Substantial differences exist in the pharmacokinetic profile of Abstral compared to other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl that could result in fatal overdose.
- When prescribing, do not convert patients on a mcg per mcg basis from any other fentanyl products to Abstral.
- When dispensing, do not substitute an Abstral prescription for other fentanyl products.
Abstral contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. Abstral can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Abstral in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.
Because of the risk for misuse, abuse, addiction, and overdose, Abstral is available only through a restricted program, required by the Food and Drug Administration, called a Risk Evaluation and Mitigation Strategy (REMS). Under the TIRF (Transmucosal Immediate Release Fentanyl) REMS Access program, outpatients, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program.
Further information is available at www.TIRFREMSAccess.com or by calling 1-866-822-1483. Parentheses refer to sections in the Full Prescribing Information.
Abstral® is a federally controlled substance (CII) available by prescription only. This information is not intended to replace discussions with your doctor.
Please see Full Prescribing Information, with Boxed Warning